Connecticut: Urge your elected officials to prioritize legalization
Marijuana is legal for adults and is taxed and regulated similarly to alcohol; state also has a medical marijuana law
Connecticut Social Equity Council members and executive director appointed
Last update: September 21, 2021
Connecticut’s Social Equity Council is now fully appointed. The Council held its first meeting on September 2, 2021. As part of Public Act 21-1, the Social Equity Council was created to ensure that the adult-use cannabis market in Connecticut is grown in an equitable fashion, providing individuals and communities most impacted by the war on drugs are granted market opportunities and funds from the adult-use program. The Social Equity Council consists of 15 members, seven of whom are appointed by the legislature, four who are appointed by the governor, and four who are ex officio members. On August 25, 2021, Gov. Lamont announced he would appoint Ginne-Rae Clay as interim executive director of the Social Equity Council.
According to the statement released by Gov. Lamont, “Clay is an accomplished senior executive with more than 35 years of expertise in government, organizational management, education, community action, and community engagement. Most recently, she served with the City of Bridgeport as the deputy director of the Office of Planning and Economic Development.”
You can view a list full list of the Social Equity Council’s members here.
Gov. Lamont signs S.B. 1201, legalizing cannabis starting July 1
On June 22, 2021, Gov. Edward “Ned” Lamont signed S.B. 1201 — “An Act Concerning the Equitable and Responsible Regulation of Cannabis” — into law, concluding a multi-year effort to legalize, regulate, and tax cannabis in the Constitution State. Earlier in June, the House and Senate passed S.B. 1201 in special session on 76-62 and16-11 votes, respectively.
Under the bill, starting July 1, adults 21 and over will be allowed to possess up to one and a half ounces on their person and up to five ounces in a locked trunk or secure location in their home. Legal sales are anticipated to begin by May 2022. Adults will be allowed to securely cultivate cannabis at home starting July 1, 2023. Additionally, 50% of the licenses will be reserved for equity applicants, and up to 75% of the revenue will be dedicated towards equity efforts and community reinvestment. You can check out a full summary of the bill here and a condensed summary here.
In addition to legalizing cannabis, S.B. 1201 includes expungement of lower-level cannabis records and dedicates the bulk of excise tax revenues into a Social Equity and Innovation Fund, which will be used to promote a diverse cannabis industry and reinvest in hard-hit communities. Half of new cannabis business licenses will be issued to social equity applicants, who can receive technical assistance, start-up funding, assistance from an accelerator program, and workforce training.
MPP is proud to have played a leading role in the multi-year effort to legalize cannabis in Connecticut, with a focus on equity and reparative justice. We are grateful to legislative leadership, the governor’s office, advocates, and lawmakers for working to get cannabis reform past the finish line and to get it done right. Many thanks to our amazing Regulate CT lobbying and advocacy team — MPP’s senior legislative counsel DeVaughn Ward; Paul Nuñez and the staff of Depino, Nuñez, and Biggs; Adam Wood of City and State Public Affairs; and Hillary Glass of Reynolds Strategy Group for all of their insight and assistance.
Congratulations to the Constitution State on this huge victory!
Medical marijuana program information; program expanded to include chronic pain
Connecticut’s medical marijuana program was originally enacted on June 1, 2012. The program protects patients and caregivers from arrest and prosecution if they have a valid registration card and if the medical marijuana was obtained from the specific dispensary where the patient is registered.
In 2016, both regulators and lawmakers expanded Connecticut’s medical marijuana program.
On June 2, 2020, the Connecticut Legislative Regulations Review Committee approved allowing medical cannabis to treat chronic pain — although it narrowly defined the term. The Board of Physicians recommended adding chronic pain as a qualifying condition on September 27, 2019. Previously, Connecticut was the only state medical marijuana program that did not permit patients to treat chronic pain with medical cannabis.
The revision permits medical cannabis to be recommended for adults with “chronic pain of at least six months duration associated with a specific underlying chronic condition refractory to other treatment intervention.” Unfortunately, that narrow definition means physicians can only recommend cannabis to patients who have sought treatment for their chronic pain for at least six months and whose pain has been resistant to other treatments.
The committee also approved the use of medical cannabis to treat Ehlers-Danlos Syndrome, an inherited disorder that weakens the body’s connective tissue and leads to weakened blood vessels and organs.
While these revisions undoubtedly expand patients’ ability to use medical cannabis to treat their aliments, Connecticut will have one of the most restrictive chronic pain provisions in the country. Patients will have to suffer for months before trying cannabis and will first be steered to far more dangerous medications.
For more information about the program, including a current list of qualifying conditions and symptoms, click here.